These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 15168594

  • 1. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera.
    Karakantza M, Giannakoulas NC, Zikos P, Sakellaropoulos G, Kouraklis A, Aktypi A, Metallinos IC, Theodori E, Zoumbos NC, Maniatis A.
    Int J Hematol; 2004 Apr; 79(3):253-9. PubMed ID: 15168594
    [Abstract] [Full Text] [Related]

  • 2. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH.
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [Abstract] [Full Text] [Related]

  • 3. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 4. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.
    Coucelo M, Caetano G, Sevivas T, Almeida Santos S, Fidalgo T, Bento C, Fortuna M, Duarte M, Menezes C, Ribeiro ML.
    Int J Hematol; 2014 Jan; 99(1):32-40. PubMed ID: 24277659
    [Abstract] [Full Text] [Related]

  • 5. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.
    Cella G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L, Barbui T, Falanga A.
    Thromb Haemost; 2010 Jul; 104(1):151-6. PubMed ID: 20431848
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH.
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.
    Villmow T, Kemkes-Matthes B, Matzdorff AC.
    Thromb Res; 2002 Nov 01; 108(2-3):139-45. PubMed ID: 12590950
    [Abstract] [Full Text] [Related]

  • 10. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.
    Falanga A, Marchetti M, Barbui T, Smith CW.
    Semin Hematol; 2005 Oct 01; 42(4):239-47. PubMed ID: 16210037
    [Abstract] [Full Text] [Related]

  • 11. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera.
    Elliott MA, Tefferi A.
    Curr Hematol Rep; 2004 Sep 01; 3(5):344-51. PubMed ID: 15341701
    [Abstract] [Full Text] [Related]

  • 12. Target hematologic values in the management of essential thrombocythemia and polycythemia vera.
    Hernández-Boluda JC, Gómez M.
    Eur J Haematol; 2015 Jan 01; 94(1):4-11. PubMed ID: 24814134
    [Abstract] [Full Text] [Related]

  • 13. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera.
    Michiels JJ, Berneman ZN, Schroyens W, Van Vliet HH.
    Platelets; 2004 Mar 01; 15(2):67-84. PubMed ID: 15154599
    [Abstract] [Full Text] [Related]

  • 14. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
    Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F.
    Am J Hematol; 2009 Feb 01; 84(2):102-8. PubMed ID: 19105233
    [Abstract] [Full Text] [Related]

  • 15. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera.
    van Genderen PJ, Michiels JJ.
    Semin Thromb Hemost; 1997 Feb 01; 23(4):357-63. PubMed ID: 9263352
    [Abstract] [Full Text] [Related]

  • 16. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.
    Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E.
    Am J Hematol; 1996 May 01; 52(1):14-20. PubMed ID: 8638606
    [Abstract] [Full Text] [Related]

  • 17. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G, Vianelli N, Guglielmelli P, Pieri L, Scognamiglio F, Rodeghiero F, Pogliani EM, Finazzi G, Gugliotta L, Marchioli R, Leone G, Barbui T, GIMEMA CMD-Working Party.
    Haematologica; 2008 Mar 01; 93(3):372-80. PubMed ID: 18268279
    [Abstract] [Full Text] [Related]

  • 18. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.
    J Clin Oncol; 2007 Mar 20; 25(9):1048-53. PubMed ID: 17369568
    [Abstract] [Full Text] [Related]

  • 19. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives.
    Landolfi R, Patrono C.
    Leuk Lymphoma; 1996 Sep 20; 22 Suppl 1():83-6. PubMed ID: 8951777
    [Abstract] [Full Text] [Related]

  • 20. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.
    Ahlstrand E, Samuelsson J, Lindgren M, Pettersson H, Liljeholm M, Ravn-Landtblom A, Scheding S, Andréasson B.
    Eur J Haematol; 2020 Mar 20; 104(3):271-278. PubMed ID: 31863513
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.